MILAN, Nov 7 (Reuters) - Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance ...

MILAN (Reuters) - Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance for next year overshadowed strong ...

Owning one of the best Wi-Fi routers in Australia is a superb way to upgrade your home internet connection. These days, more Aussies spend a significant amount of their time online, especially if ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

The best mesh Wi-Fi systems give you a strong wireless signal in every room and even out in the backyard When you purchase through links on our site, we may earn an affiliate commission. Here’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...